Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 8/20 | 0.31 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17016783 | 0.94 | TUBB1 (0.34) | TUBB1FGFR2FGFR1ESR1KDM4E | |
| SCHEMBL17016803 | 0.87 | TUBB1 (0.43) | TUBB1FGFR2FGFR1ESR1PKM | |
| SCHEMBL17016776 | 0.81 | TUBB1 (0.37) | TUBB1FGFR2FGFR1ESR1KDM4E | |
| SCHEMBL18509967 | 0.81 | FGFR2 (0.39) | TUBB1FGFR2FGFR1PKMKDM4E | |
| SCHEMBL12907042 | 0.78 | TUBB1 (0.46) | TUBB1FGFR2FGFR1PKMKDM4E | |
| SCHEMBL17791124 | 0.78 | FGFR2 (0.41) | FGFR2FGFR1KDM4EGAAKMT2A | |
| SCHEMBL21609904 | 0.78 | FGFR2 (0.44) | FGFR2FGFR1KDM4EKMT2AALOX5AP | |
| SCHEMBL8932743 | 0.77 | ALDH1A1 (0.48) | TUBB1FGFR2FGFR1KDM4EGAA | |
| SCHEMBL17016796 | 0.77 | RARB (0.36) | FGFR2FGFR1ESR1 | |
| SCHEMBL17791126 | 0.76 | FGFR2 (0.41) | FGFR2FGFR1KDM4EKMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9404040-B2 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232759-A1 | Liquid crystal compound having fluorine-containing alkenyl terminal group, liquid crystal composition and liquid crystal display device | PYM1, CXCR1, LEO1 | TUBB1 2393/4885FGFR2 243/4885FGFR1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.